Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Braun‐Moscovici, Yolanda; Kaplan, Marielle; Braun, Maya; Markovits, Doron; Giryes, Sami; Toledano, K.; Tavor, Yonit; Dolnikov, Katya; Balbir‐Gurman, Alexandra

doi:10.1136/annrheumdis-2021-220503

Cited by 166 publications

(225 citation statements)

References 15 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…Despite this, vaccine hesitancy remains an alarming problem worldwide. Data regarding COVID-19 vaccine efficacy and adverse events (AE) in patients with autoimmune and inflammatory rheumatic diseases (AIIRD) have been published recently although these mostly include the mRNA vaccines (Pfizer-BioNTech and Moderna) and the ChAdOx1 nCoV-19/AZD1222 (Oxford/AstraZeneca) [6][7][8][9]. Many other vaccines are being administered worldwide and data in AIIRD population are limited.…”

Section: Introductionmentioning

confidence: 99%

Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study

et al. 2021

View full text Add to dashboard Cite

Data regarding COVID-19 vaccine efficacy and adverse events (AE) in patients with autoimmune and inflammatory rheumatic diseases (AIIRD) have been published recently although these mostly include the mRNA vaccines (Pfizer-BioNTech and Moderna) and the ChAdOx1 nCoV-19/AZD1222 (Oxford-AstraZeneca). This research aimed to study the prevalence of AE presented with six different SARS-CoV-2 vaccines {ChadOX1 nCoV-19 (AZD1222), Ad5-nCoV2, Ad26.COV2.S, mRNA-1273, BNT162b2, and CoronaVac} in Mexican patients with AIIRD. We performed a cross-sectional study about vaccine history. Two hundred and twenty five consecutive patients were recruited, mean age was 50.7 years and the majority (n = 213; 94.6%) were females. One hundred and seven (47.5%) received BNT162b2 mRNA, 34 (15.1%) Ad5-nCoV, 29 (12.8%) mRNA-1273, 28 (12.4%) ChAdOX1 nCoV-19 (AZD1222), 22 (9.7%) CoronaVac and 5 (2.2%) Ad26.COV2.S. The vaccines that had the most AE proportionally to the number of patients vaccinated were Janssen (5; 100%) followed by Pfizer-BioNTEch (86; 80%) and CanSinoBIO (27; 79.4%). Localized pain was the most frequent (158; 70.2%) AE. Fatigue (78; 34.7%), headache (69; 30.6%) and muscle ache (66; 29.3%) were the most common systemic symptoms. No serious AE that required medical attention or hospitalization were reported. The current results support the safety of different COVID-19 vaccines in patients with AIIRD. This information can help fight vaccine hesitancy in this population. KeywordsCOVID-19 vaccines • SARS-CoV-2 • Vaccine hesitancy • Autoimmune rheumatic diseases • Drug-related side effects and adverse reactions Rheumatology INTERNATIONAL

show abstract

Section: Introductionmentioning

confidence: 99%

Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In particular, BNT162b2 elicited strong antibody responses; one week after the second dose, the geometric mean of the 50% neutralization titers of SARS-CoV-2 serum was up to 3.3-fold higher than that observed in samples from individuals who recovered from COVID-19 and also showed poly-specific cellular immunity [ 71 ]. In contrast, most patients on maintenance hemodialysis developed a substantial humoral response after administration of the BNT162b2 vaccine and it was significantly lower than in the control [ 72 ], whereas 86% of patients with inflammatory rheumatic diseases developed a humoral response following the administration of the second dose of the BNT162b2 vaccine [ 73 ].…”

Section: Humoral Immune Response After Covid-19 Vaccinationmentioning

confidence: 99%

Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination

Altawalah

2021

Vaccines

View full text Add to dashboard Cite

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19). The clinical severity of COVID-19 ranges from asymptomatic to critical disease and, eventually, death in smaller subsets of patients. The first case of COVID-19 was declared at the end of 2019 and it has since spread worldwide and remained a challenge in 2021, with the emergence of variants of concern. In fact, new concerns were the still unclear situation of SARS-CoV-2 immunity during the ongoing pandemic and progress with vaccination. If maintained at sufficiently high levels, the immune response could effectively block reinfection, which might confer long-lived protection. Understanding the protective capacity and the duration of humoral immunity during SARS-CoV-2 infection or after vaccination is critical for managing the pandemic and would also provide more evidence about the efficacy of SARS-CoV-2 vaccines. However, the exact features of antibody responses that govern SARS-CoV-2 infection or after vaccination remain unclear. This review summarizes the main knowledge that we have about the humoral immune response during COVID-19 disease or after vaccination. Such knowledge should help to optimize vaccination strategies and public health decisions.

show abstract

“…There is few research hitherto about MG course after COVID-19 vaccination. Several studies investigating the safety of SARS-CoV-2 mRNA vaccines in patients with stable RMDs revealed minor side effects and no distinct impact on RMD activity (109,110). A recent multicenter study reported no evidence of significant disease flares, but the occurrence of herpes zoster after BNT162b2 mRNA vaccination in subjects with low and even no IST is worth investigating (80).…”

Section: Safety Of Sars-cov-2 Vaccines In Mgmentioning

confidence: 99%

To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis

Zhou

Yang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and abnormal fatigability due to the antibodies against postsynaptic receptors. Despite the individual discrepancy, patients with MG share common muscle weakness, autoimmune dysfunction, and immunosuppressive treatment, which predispose them to infections that can trigger or exacerbate MG. Vaccination, as a mainstay of prophylaxis, is a major management strategy. However, the past years have seen growth in vaccine hesitancy, owing to safety and efficacy concerns. Ironically, vaccines, serving as an essential and effective means of defense, may induce similar immune cross-reactivity to what they are meant to prevent. Herein, we outline the progress in vaccination, review the current status, and postulate the clinical association among MG, vaccination, and immunosuppression. We also address safety and efficacy concerns of vaccination in MG, in relation to COVID-19. Since only a handful of studies have reported vaccination in individuals with MG, we further review the current clinical studies and guidelines in rheumatic diseases. Overall, our reviews offer a reference to guide future vaccine clinical decision-making and improve the management of MG patients.

show abstract

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Cited by 166 publications

References 15 publications

Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study

Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study

Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination

To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis

Contact Info

Product

Resources

About